Endogenous GC surge can subvert anticancer therapy-induced immunity and abolish therapeutic control of tumors in animal models through blocking type I IFN responses in dendritic cell and IFN-γ+ T cell activation, accompanied with cancer progression (24, 42). This evidence concerns the gene IFNG and cancer.